Ipamorelin is a selective growth‑hormone secretagogue that users take mainly for muscle growth, fat loss, and improved sleep‑quality/recovery, with smaller numbers reporting joint repair or general wellness benefits. The community‑driven regimen centers on a daily dose of about 200 µg (range 60 µg–25 mg), often cycled 5 days on / 2 days off, though exact timing varies. The principal limitation is that human data are sparse and off‑label; no FDA‑approved indication exists and most exploratory studies lack published results. Users most frequently note changes in sleep and vivid dreams, while isolated reports mention occasional flushing or mild edema, and injection‑site irritation has not emerged as a consistent issue.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Ipamorelin possesses limited human evidence, restricted primarily to diagnostic, mechanistic, and small-scale treatment studies. While the literature includes two completed registered trials, the clinical data remains thin, with most indications supported by only a single study or confined to preclinical research. This lack of large-scale, multi-trial validation means that while the peptide has been investigated for applications like gastrointestinal dysmotility and ileus, it lacks the robust, high-tier evidence required to establish consistent clinical efficacy.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Gastrointestinal Dysmotility
1 study · 1 completed
Ileus
1 study · 1 completed
Treatment studies
1 study
Diagnostic & mechanistic studies
2 studies
2 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 29 out-of-stock offers not shown
How Ipamorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In research trials, Ipamorelin was administered intravenously at a dose of 0.03–0.06 mg per kilogram of body weight, given two to three times each day.
No structured protocol details captured for this tier yet.
Most community reports did not specify a schedule; among those that did, daily dosing (≈200 mcg) was most common, with a smaller group using it twice daily. A minority followed a 5‑days‑on/2‑days‑off cycle, while the majority used it continuously.